Repare Operating Income vs Research Development Analysis

RPTX Stock

USD 3.32 0.17 5.40%

Repare Therapeutics financial indicator trend analysis is much more than just breaking down Repare Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Repare Therapeutics is a good investment. Please check the relationship between Repare Therapeutics Operating Income and its Research Development accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.

Operating Income vs Research Development

Operating Income vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Repare Therapeutics Operating Income account and Research Development. At this time, the significance of the direction appears to have pay attention.

The correlation between Repare Therapeutics' Operating Income and Research Development is -0.85. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Research Development in the same time period over historical financial statements of Repare Therapeutics, assuming nothing else is changed. The correlation between historical values of Repare Therapeutics' Operating Income and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Repare Therapeutics are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Operating Income i.e., Repare Therapeutics' Operating Income and Research Development go up and down completely randomly.

Correlation Coefficient

-0.85

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from Repare Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Repare Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Research Development

Most indicators from Repare Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Repare Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Repare Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Repare Stock please use our How to Invest in Repare Therapeutics guide.Tax Provision is likely to drop to about 2.8 M in 2024. Selling General Administrative is likely to drop to about 18.4 M in 2024

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	1.5M	2.0M	1.9M	1.2M
Total Operating Expenses	116.3M	151.6M	167.4M	84.1M

Reconciled Depreciation Total Operating Expenses

Repare Therapeutics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Common Stock Shares Outstanding		0.92	0.83	0.78	0.85	0.51	0.86	0.88	-0.78	-0.84	0.56	0.8	0.86	0.62	0.53	0.91	0.7	0.87	0.07	0.87	0.88	0.73	0.68	0.85	0.9	0.92
Total Assets	0.92		0.84	0.8	0.98	0.68	0.95	0.98	-0.91	-0.82	0.47	0.93	0.95	0.5	0.68	1.0	0.61	0.93	-0.13	0.86	0.99	0.66	0.49	0.98	0.91	1.0
Other Current Liab	0.83	0.84		0.91	0.87	0.28	0.91	0.86	-0.61	-0.93	0.32	0.64	0.85	0.66	0.46	0.83	0.69	0.92	-0.43	0.94	0.84	0.84	0.24	0.87	0.94	0.84
Total Current Liabilities	0.78	0.8	0.91		0.8	0.16	0.8	0.79	-0.52	-0.82	0.0	0.55	0.73	0.46	0.31	0.8	0.52	0.82	-0.4	0.85	0.77	0.74	0.34	0.8	0.78	0.81
Total Stockholder Equity	0.85	0.98	0.87	0.8		0.67	0.98	0.96	-0.88	-0.82	0.42	0.9	0.94	0.49	0.66	0.98	0.61	0.94	-0.3	0.84	0.99	0.66	0.31	1.0	0.92	0.98
Other Liab	0.51	0.68	0.28	0.16	0.67		0.61	0.67	-0.91	-0.23	0.6	0.87	0.69	0.01	0.82	0.68	0.14	0.46	0.26	0.28	0.71	0.01	0.37	0.67	0.51	0.68
Net Tangible Assets	0.86	0.95	0.91	0.8	0.98	0.61		0.93	-0.83	-0.86	0.47	0.84	0.92	0.57	0.61	0.95	0.67	0.95	-0.33	0.87	0.97	0.72	0.26	0.98	0.96	0.95
Property Plant And Equipment Net	0.88	0.98	0.86	0.79	0.96	0.67	0.93		-0.91	-0.82	0.5	0.93	0.99	0.49	0.78	0.97	0.57	0.92	-0.15	0.87	0.97	0.64	0.46	0.96	0.92	0.97
Net Debt	-0.78	-0.91	-0.61	-0.52	-0.88	-0.91	-0.83	-0.91		0.56	-0.6	-0.99	-0.91	-0.25	-0.87	-0.91	-0.37	-0.74	-0.12	-0.62	-0.91	-0.34	-0.51	-0.88	-0.77	-0.91
Retained Earnings	-0.84	-0.82	-0.93	-0.82	-0.82	-0.23	-0.86	-0.82	0.56		-0.45	-0.63	-0.81	-0.86	-0.36	-0.81	-0.89	-0.96	0.41	-0.99	-0.81	-0.96	-0.27	-0.82	-0.93	-0.81
Accounts Payable	0.56	0.47	0.32	0.0	0.42	0.6	0.47	0.5	-0.6	-0.45		0.62	0.58	0.56	0.58	0.45	0.58	0.48	0.32	0.44	0.49	0.37	0.39	0.42	0.6	0.46
Cash	0.8	0.93	0.64	0.55	0.9	0.87	0.84	0.93	-0.99	-0.63	0.62		0.93	0.36	0.84	0.93	0.47	0.8	0.06	0.69	0.93	0.44	0.51	0.9	0.8	0.93
Non Current Assets Total	0.86	0.95	0.85	0.73	0.94	0.69	0.92	0.99	-0.91	-0.81	0.58	0.93		0.51	0.82	0.95	0.59	0.91	-0.13	0.87	0.95	0.64	0.44	0.94	0.94	0.95
Non Currrent Assets Other	0.62	0.5	0.66	0.46	0.49	0.01	0.57	0.49	-0.25	-0.86	0.56	0.36	0.51		0.07	0.48	0.98	0.75	-0.35	0.79	0.51	0.93	0.11	0.49	0.7	0.5
Other Assets	0.53	0.68	0.46	0.31	0.66	0.82	0.61	0.78	-0.87	-0.36	0.58	0.84	0.82	0.07		0.68	0.12	0.52	0.17	0.46	0.68	0.12	0.39	0.66	0.62	0.67
Cash And Short Term Investments	0.91	1.0	0.83	0.8	0.98	0.68	0.95	0.97	-0.91	-0.81	0.45	0.93	0.95	0.48	0.68		0.6	0.92	-0.13	0.85	0.99	0.65	0.5	0.98	0.9	1.0
Net Receivables	0.7	0.61	0.69	0.52	0.61	0.14	0.67	0.57	-0.37	-0.89	0.58	0.47	0.59	0.98	0.12	0.6		0.82	-0.34	0.82	0.63	0.94	0.16	0.61	0.76	0.61
Common Stock Total Equity	0.87	0.93	0.92	0.82	0.94	0.46	0.95	0.92	-0.74	-0.96	0.48	0.8	0.91	0.75	0.52	0.92	0.82		-0.38	0.96	0.94	0.87	0.28	0.94	0.96	0.93
Non Current Liabilities Total	0.07	-0.13	-0.43	-0.4	-0.3	0.26	-0.33	-0.15	-0.12	0.41	0.32	0.06	-0.13	-0.35	0.17	-0.13	-0.34	-0.38		-0.35	-0.21	-0.48	0.71	-0.3	-0.26	-0.13
Capital Surpluse	0.87	0.86	0.94	0.85	0.84	0.28	0.87	0.87	-0.62	-0.99	0.44	0.69	0.87	0.79	0.46	0.85	0.82	0.96	-0.35		0.84	0.92	0.34	0.84	0.93	0.85
Other Current Assets	0.88	0.99	0.84	0.77	0.99	0.71	0.97	0.97	-0.91	-0.81	0.49	0.93	0.95	0.51	0.68	0.99	0.63	0.94	-0.21	0.84		0.65	0.38	0.99	0.92	0.99
Other Stockholder Equity	0.73	0.66	0.84	0.74	0.66	0.01	0.72	0.64	-0.34	-0.96	0.37	0.44	0.64	0.93	0.12	0.65	0.94	0.87	-0.48	0.92	0.65		0.16	0.66	0.8	0.66
Total Liab	0.68	0.49	0.24	0.34	0.31	0.37	0.26	0.46	-0.51	-0.27	0.39	0.51	0.44	0.11	0.39	0.5	0.16	0.28	0.71	0.34	0.38	0.16		0.31	0.34	0.49
Net Invested Capital	0.85	0.98	0.87	0.8	1.0	0.67	0.98	0.96	-0.88	-0.82	0.42	0.9	0.94	0.49	0.66	0.98	0.61	0.94	-0.3	0.84	0.99	0.66	0.31		0.92	0.98
Property Plant And Equipment Gross	0.9	0.91	0.94	0.78	0.92	0.51	0.96	0.92	-0.77	-0.93	0.6	0.8	0.94	0.7	0.62	0.9	0.76	0.96	-0.26	0.93	0.92	0.8	0.34	0.92		0.91
Total Current Assets	0.92	1.0	0.84	0.81	0.98	0.68	0.95	0.97	-0.91	-0.81	0.46	0.93	0.95	0.5	0.67	1.0	0.61	0.93	-0.13	0.85	0.99	0.66	0.49	0.98	0.91

Click cells to compare fundamentals

Repare Therapeutics Account Relationship Matchups

Repare Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	36.7M	36.9M	37.8M	41.9M	42.1M	35.7M
Total Assets	102.7M	357.1M	368.7M	364.1M	253.9M	267.7M
Other Current Liab	4K	5.3M	16.9M	19.5M	21.7M	11.7M
Total Current Liabilities	4.2M	11.0M	35.1M	78.6M	39.1M	31.2M
Total Stockholder Equity	(46.1M)	286.8M	288.4M	279.5M	212.1M	183.0M
Other Liab	8.1M	55.9M	39.6M	2.7M	3.1M	2.9M
Net Tangible Assets	(46.1M)	286.8M	288.4M	279.5M	321.4M	173.0M
Property Plant And Equipment Net	3.4M	8.6M	13.1M	9.6M	7.5M	8.1M
Net Debt	(93.7M)	(322.2M)	(327.1M)	(154.1M)	(107.9M)	(113.3M)
Retained Earnings	(49.9M)	(103.4M)	(210.3M)	(239.3M)	(333.1M)	(316.5M)
Accounts Payable	2.1M	2.3M	2.3M	461K	2.4M	2.0M
Cash	94.8M	326.2M	334.4M	159.5M	111.3M	190.1M
Non Current Assets Total	4.1M	10.5M	17.3M	10.1M	10.2M	9.9M
Non Currrent Assets Other	567K	500K	586K	497K	2.7M	2.8M
Other Assets	699K	1.9M	4.2M	497K	571.6K	543.0K
Cash And Short Term Investments	94.8M	333.7M	341.9M	343.9M	223.6M	247.3M
Net Receivables	3.1M	6.2M	3.2M	4.3M	15.3M	16.1M
Liabilities And Stockholders Equity	102.7M	357.1M	368.7M	364.1M	253.9M	267.7M
Non Current Liabilities Total	144.6M	59.2M	45.2M	5.9M	2.7M	2.6M
Capital Lease Obligations	1.1M	4.0M	7.3M	5.4M	3.4M	3.9M
Other Current Assets	719K	6.7M	6.3M	5.7M	4.7M	4.5M
Other Stockholder Equity	3.8M	5.9M	18.0M	37.2M	61.8M	64.9M
Total Liab	148.8M	70.3M	80.3M	84.6M	41.8M	61.6M
Net Invested Capital	(46.1M)	286.8M	288.4M	279.5M	212.1M	183.0M
Property Plant And Equipment Gross	3.4M	8.6M	13.1M	9.6M	14.8M	9.4M
Total Current Assets	98.6M	346.6M	351.4M	354.0M	243.7M	257.8M
Net Working Capital	94.3M	335.5M	316.3M	275.4M	204.6M	226.7M
Property Plant Equipment	3.4M	8.6M	5.6M	9.6M	11.0M	6.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Repare Stock Analysis

When running Repare Therapeutics' price analysis, check to measure Repare Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repare Therapeutics is operating at the current time. Most of Repare Therapeutics' value examination focuses on studying past and present price action to predict the probability of Repare Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repare Therapeutics' price. Additionally, you may evaluate how the addition of Repare Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Repare Operating Income vs Research Development Analysis

Operating Income vs Research Development

Operating Income vs Research Development Correlation Analysis

Correlation Coefficient

Operating Income

Research Development

Repare Therapeutics fundamental ratios Correlations

Repare Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Repare Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Repare Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Current Assets	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Total Stockholder Equity

Capital Surpluse	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Common Stock Total Equity	- 0.96	Retained Earnings
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Other Current Liab